Results 21 to 30 of about 1,991 (194)

Emerging Medical Treatment for Hypertrophic Cardiomyopathy [PDF]

, 2021
Hypertrophic cardiomyopathy (HCM) is a common myocardial disease characterized by otherwise unexplained left ventricular hypertrophy. The main cause of disabling symptoms in patients with HCM is left ventricular outflow tract (LVOT) obstruction.
Bacchi, Beatrice, Berteotti, Martina, Cappelli, Francesco, Marchi, Alberto, Marchionni, Niccolò, Olivotto, Iacopo, Stefàno, Pierluigi, Tassetti, Luigi, Zampieri, Mattia, Zocchi, Chiara   +9 more
core   +1 more source

Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy [PDF]

, 2022
Cardiomyopathies have unresolved genotype–phenotype relationships and lack disease-specific treatments. Here we provide a framework to identify genotype-specific pathomechanisms and therapeutic targets to accelerate the development of precision medicine.
Bueno-Orovio, Alfonso, Doste, Ruben, Garfinkel, Amanda C, Margara, Francesca, Psaras, Yiangos, Repetti, Giuliana G, Rodriguez, Blanca, Schmid, Manuel, Seidman, Christine E, Seidman, Jonathan G, Toepfer, Christopher N, Wang, Zhinuo Jenny   +11 more
core   +2 more sources

A New Chapter in the Management of Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors [PDF]

, 2023
In the recent years, there has been a significant breakthrough in the treatment of hypertrophic cardiomyopathy. New precision molecules have been developed and successfully applied in clinical trials. A new class of orally available allosteric inhibitors
Olivotto Iacopo, Pálinkás Eszter Dalma, Sepp Róbert   +2 more
core   +1 more source

Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial [PDF]

, 2023
IMPORTANCE: Mavacamten, a cardiac myosin inhibitor, improved peak oxygen uptake (pVO2) in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in the EXPLORER-HCM study.
Olivotto, Iacopo
core   +4 more sources

Mavacamten for hypertrophic obstructive cardiomyopathy – Authors' reply [PDF]

The Lancet, 2021
reply to ...
Jacoby D., Ho C. Y., Lester S. J., Wang A., Olivotto I.   +4 more
openaire   +2 more sources

Analyzing safety and effectiveness of Mavacamten in comparison with placebo for managing hypertrophic cardiomyopathy: a systemic review and meta-analysis

The Egyptian Heart Journal, 2023
Background Hypertrophic cardiomyopathy (HCM) is a hereditary myocardial disorder, often due to sarcomere gene mutations, characterized by the left ventricular hypertrophy. Current treatments offer symptomatic relief but lack specificity.
Hussain Sohail Rangwala, Hareer Fatima, Mirha Ali, Syed Taha Ahmed, Burhanuddin Sohail Rangwala, Syed Raza Abbas   +5 more
doaj   +1 more source

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy [PDF]

, 2023
Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic New York Heart Association Classes II and III obstructive hypertrophic cardiomyopathy
Abraham, Theodore P, Braunwald, Eugene, Elliott, Perry M, Olivotto, Iacopo, Saberi, Sara   +4 more
core   +4 more sources

Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials

The Egyptian Heart Journal, 2023
Background Mavacamten, an allosteric myosin inhibitor, is considered to be a promising drug for the treatment of hypertrophic cardiomyopathy (HCM). This meta-analysis aimed to explore the safety and efficacy of mavacamten in HCM patients.
Mehrdad Rabiee Rad, Ghazal Ghasempour Dabaghi, Danial Habibi   +2 more
doaj   +1 more source

Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy

BMJ Open, 2023
Introduction Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease commonly caused by pathogenic genetic variants encoding sarcomere proteins.
Qing Zhang, Fang Wang, Yaling Han, Jing Sun, Shuyang Zhang, Wei Jin, Zhuang Tian, Ping Yang, Geng Wang, Jingmin Zhou, Peiwen Hsu   +10 more
doaj   +1 more source

Is mavacamten superior to aficamten for hypertrophic cardiomyopathy? A frequentist network meta-analysis [PDF]

Exploration of Cardiology
Background: Myosin inhibitors have been shown to improve exercise capacity and symptoms, as well as reduce the left ventricular outflow tract (LVOT) gradient. This study explores the efficacy of mavacamten versus aficamten in hypertrophic cardiomyopathy (
Ayesha Aman, Bisma Akram, Arfa Akram, Momina Maham, Eisha Tariq, Aimen Hassan, Masooma Zainab Bokhari, Aleena Akram, Sania Akram, Malik Waleed Zeb Khan   +9 more
doaj   +1 more source